From Wikipedia, the free encyclopedia
Jump to: navigation,
search
Pravastatin
 |
| Systematic (IUPAC) name |
| (3R,5R)-3,5-dihydroxy-7-((1R,2S,6S,8R,8aR)-6-hydroxy-2-methyl-8-{[(2S)-2-methylbutanoyl]oxy}-1,2,6,7,8,8a-hexahydronaphthalen-1-yl)-heptanoic acid |
| Identifiers |
| CAS number |
81093-37-0 |
| ATC code |
C10AA03 |
| PubChem |
CID 54687 |
| DrugBank |
APRD00328 |
| Chemical data |
| Formula |
C23H36O7 |
| Mol. mass |
424.528 g/mol |
| SMILES |
eMolecules & PubChem |
| Pharmacokinetic data |
| Protein binding |
50% |
| Half-life |
77 hours |
| Therapeutic considerations |
| Pregnancy cat. |
? |
| Legal status |
|
 Y(what is this?) (verify)
|
Pravastatin (marketed as Pravachol or Selektine) is a member of the drug class of statins, used for lowering cholesterol and preventing cardiovascular disease. Initially known as CS-514, it was originally identified in a bacterium called Nocardia autotrophica by researchers of the Sankyo Pharma Inc..1 It is presently being marketed outside Japan by the pharmaceutical company Bristol-Myers Squibb.
The U.S. Food and Drug Administration approved generic pravastatin for sale in the United States for the first time on April 24, 2006. Generic pravastatin sodium tablets (10 mg, 20 mg and 40 mg) are manufactured by TEVA Pharmaceuticals in Kfar Sava, Israel.2
References
- ^ Yoshino G, Kazumi T, Kasama T, et al. (1986). "Effect of CS-514, an inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase, on lipoprotein and apolipoprotein in plasma of hypercholesterolemic diabetics". Diabetes Res. Clin. Pract. 2 (3): 179–81. doi:10.1016/S0168-8227(86)80020-1. PMID 3091343.
- ^ "FDA Approves First Generic Pravastatin". http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2006/ucm108644.htm. Retrieved 2008-01-20.
External links
- Pravachol information from the National Institute of Health
- Package insert for Pravachol
|
Lipid modifying agents (C10) |
|
| GI tract |
|
Cholesterol absorption inhibitor, NPC1L1
|
Ezetimibe • SCH-48461
|
|
|
Bile acid sequestrants/resins (LDL)
|
Cholestyramine • Colestipol • Colestilan • Colextran • Colesevelam
|
|
|
| Liver |
|
Statins (HMG-CoA reductase, LDL)
|
Simvastatin# • Atorvastatin • Fluvastatin • Lovastatin • Mevastatin • Pitavastatin • Pravastatin • Rosuvastatin • Cerivastatin‡
|
|
|
Niacin and derivatives (HDL and LDL)
|
Niceritrol • Niacin • Nicofuranose • Aluminium nicotinate • Nicotinyl alcohol • Acipimox
|
|
|
| Blood vessels |
|
Fibrates (PPAR)
|
Clofibrate‡ • Bezafibrate • Aluminium clofibrate • Gemfibrozil • Fenofibrate • Simfibrate • Ronifibrate • Ciprofibrate • Etofibrate • Clofibride • Clinofibrate
|
|
|
CETP inhibitors (HDL)
|
Anacetrapib† • Torcetrapib§ • JTT-705
|
|
|
| Combinations |
Niacin/lovastatin • Niacin/simvastatin • Ezetimibe/simvastatin • Niacin/laropiprant
|
|
| Other |
Dextrothyroxine • Probucol • Tiadenol • Benfluorex • Meglutol • Omega-3-triglycerides • Magnesium pyridoxal 5-phosphate glutamate • Policosanol • Lapaquistat§ • Alipogene tiparvovec
|
|
|
#WHO-EM. ‡Withdrawn from market. Clinical trials: †Phase III. §Never to phase III
|
|
|
|
mt, a/u/y/n/h, r/g/c/p/i, f/s/l/o, m
|
au/y/n/h, rgcp/i, f/s/l/o, m, epon
|
meds(A16, C10),intm(a/u/y/n/h, r/g/c/p/i, f/s/o)
|
|
|
|
